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Agingisthemostsigniﬁcantriskfactorforarangeofdegenerative diseasesuchascardiovascular,neurodegenerative andmetabolic
disorders. While the cause of aging and its associated diseases is multifactorial, mitochondrial dysfunction has been implicated
in the aging process and the onset and progression of age-associated disorders. Recent studies indicate that maintenance of
mitochondrial function is beneﬁcial in the prevention or delay of age-associated diseases. A central molecule seems to be the
peroxisome proliferator-activated receptor γ coactivator α (PGC-1α), which is the key regulator of mitochondrial biogenesis.
Besides regulating mitochondrial function, PGC-1α targets several other cellular processes and thereby inﬂuences cell fate on
multiple levels. This paper discusses how mitochondrial function and PGC-1α are aﬀected in age-associated diseases and how
modulation of PGC-1α might oﬀer a therapeutic potential for age-related pathology.
1.Introduction
In the last 20 years, mitochondrial dysfunction has been
recognizedasan importantcontributortoanarrayofhuman
pathologies [1–3]. Mitochondrial dysfunction is particularly
associated with the onset and progression of many age-
related disorders such as neurodegenerative and cardio-
vascular diseases as well as metabolic disorders and age-
related muscle wasting. In most cases it is not clear if the
mitochondrial dysfunction is causative of the disease or if it
is a secondary eﬀect of the disease. Also, it is not understood
if mitochondrial dysfunction is an aggravating factor in
disease progression. Recent work suggests that maintenance
of mitochondrial function is beneﬁcial in at least some age-
related diseases [4]. The peroxisome proliferator-activated
receptor (PPAR) γ coactivator α (PGC-1α) integrates reg-
ulation of mitochondrial function into the modulation of
diﬀerent, tissue-speciﬁc metabolic pathways and thereby
links mitochondrial function to important cellular signaling
pathways that ultimately control cell survival [5, 6]. The fol-
lowing review discusses how mitochondrial dysfunction is
associated with age-related diseases and what impact PGC-
1α and its targets have in these diseases and their prevention.
2.Mitochondrial Function,ROS,and Aging
2.1. Mitochondrial Function and OXPHOS. Mitochondria
play a central role in the cell metabolism: besides being key
playerinapoptosis,mitochondria housemajorcellularmeta-
bolic pathways. The fatty acid oxidation and citric acid cycle
convert nutrients absorbed from ingested food to electron
donors to NADH and FADH. These redox equivalents are
fed into the oxidative phosphorylation system (OXPHOS),
which supplies the majority of the cellular ATP supply. Here
electrons are transferred from the substrates NADH and
FADH via OXPHOS complex I-IV to the terminal electron
acceptoroxygen.Duringthisprocess, protonsare transferred
from across the inner membrane generating a proton gra-
dient. This gradient is the driving force for complex V, the
ATP-Synthase, to synthesize ATP [7].
2.2. Mitochondrial ROS ProductionandMitochondrial Theory
of Aging. Since OXPHOS complexes I-IV transfer electrons
and consume most of the cellular oxygen, it is assumed that
OXPHOS is the main cellular producer of reactive oxygen
species (ROS) [8]. Leakage of electrons from the electron
transfer chain can reduce oxygen to form the superoxide2 Journal of Aging Research
anionradical. Superoxideproductionprecedesreactions that
form more reactive and potentially more dangerous ROS
such as hydroxyl radical and hydrogen peroxide [9]. The
superoxide anion can also oxidize cellular sulphite and nitric
oxide resulting in further ROS [9].
The cells and in particular mitochondria have an anti-
oxidant program to remove ROS. Superoxide dismutases
(SODs)convertsuperoxideintohydrogenperoxide,which in
turn is transformed into water by catalase or by peroxidases
such as glutathione peroxidase (GPX). Additionally, several
small molecules have ROS scavenging activity such as ﬂavo-
noids, glutathione, and ascorbate [10].
Under physiological conditions, ROS production is esti-
mated to be ∼0.2% to 5% of the consumed oxygen[11]. The
mitochondrial theory of aging states that since mitochondria
are themajorsite ofROSproductionin thecell,theorganelle
is the prime target for oxidative damage leading to oxidized
damaged lipids, proteins and nucleic acids resulting in dys-
functional mitochondria [12]. A vicious cycle is thought to
occur, as oxidative stress leads to mitochondrial (mt) DNA
mutations, which in turn can result in enzymatic abnormali-
ties and further oxidative stress. While links between aging
and oxidative stress are not new and were proposed over
50 years ago, there is much debate over whether mitochon-
drial changes are causes of aging or merely characteristics
of aging. The relationship between ROS-induced damage,
mitochondrial function and aging remains still unclear and
the contribution of ROS in the aging process is poorly
understood.
Dysfunctional mitochondria do not necessarily produce
more ROS. There are in fact many examples of mouse model
with dysfunctional OXPHOS that only have minor or no
oxidative stress [13–15]. One notable study in mice with
depleted proofreading function of the mitochondrial DNA
polymerase γ (POLG) demonstrated shortened lifespan but
no increase in reactive oxygen species despite increasing
mtDNA mutations, suggesting that mtDNA mutations can
cause lifespan shortening by other mechanisms [14]. How-
ever, it should be noted that this particular mouse models
acquires a mtDNA mutation load that is much higher
than observed in aged individuals. Although the POLG
mice develop age-like symptoms, the questions remain, how
“normal” aging is driven and what role ROS plays in the
“normal” aging process.
Humans and model organisms alike accumulate oxida-
tivedamage tolipids, proteinsand nucleicacidsduring aging
supportingthemitochondrial theory ofaging[16].However,
animal models with decreased antioxidant defense have
increased oxidative stress, but with a normal lifespan and
reproduction rate [17, 18]. Data from mice overexpressing
antioxidant enzymes are conﬂicting: mice overexpressing
superoxide dismutases have decreased ROS production, but
failtogetanextendedlifespan[19,20].Incontrast,micewith
mitochondrially targeted catalase (mCAT) have extended
lifespan and seem to have a decreased susceptibility towards
age-associated pathologies such cancer and cardiomyopathy
associated with decreased oxidative damage [21–24].
The eﬀect of ROS on lifespan regulation might be tissue
speciﬁc. ROS seems to play a role in stem cell aging. SOD2
deﬁcient hematopoietic stem cells have impaired capacity
to maintain red blood cell homeostasis and an increase
in ROS levels has been associated with impaired stem cell
function [25]. Mitochondrial dysfunction associated with
oxidative damage is suggested to play a central role in the
aging process of cochlear cells and thus play an important
role in age-related hearing loss [26]. Several studies have
shown that ROS are generated in cochlear exposed to high-
intensity noise and that cochlear hair cell loss is enhanced in
mice lacking SOD1 [27], whereas mCAT mice have reduced
cochlear cell damage in mice suggesting that mitochondrial
ROS may play a role in age-related hearing loss [28]. In the
murine aging heart, over-expression of mCAT attenuated
age-related changes including decline of diastolic function,
myocardial performance as well as ventricular ﬁbrosis [22,
23]. These ﬁndings suggest that mitochondrial ROS and/or
the mitochondrial antioxidant defense together with the
protein degradation and protein synthesis machinery to
remove and replenish oxidized protein partially might be
involved in the development of the phenotype.
While increased ROS and antioxidant defense aggravate
phenotypes in mouse model of several degenerative diseases
such as ALS and Alzheimer’s [29–32], it is still under debate
what happens during “normal” aging [33]. Short-term ROS
production is apparently important in prevention of aging
by induction of a process named mitohormesis and redox
signaling [34]. This process seems to be particulary impor-
tant for the insulin sensitizing eﬀect of exercise [35]. Recent
evidence suggests that suppression of ROS production fails
to extend lifespan in worms and may even decrease lifespan
in humans, presumably due to the reduction of the ROS
signaling, which seems to be important for diﬀerent cellular
processes [36, 37]. ROS is also an important signal for
induction of autophagy: starvation-induced autophagy can
be suppressed by antioxidants suppressing the well-known
prosurvival function of starvation-induced autophagy [38].
ROS is also involved in the regulation of the insulin/IGF-1
pathway [39].
Anotherfactorthatisdiscussedforplayingaroleinmito-
chondrial ROS production is the 66kDA isoform of the
growth factor adaptor shc (p66shc). p66shc is activated by
stress and generates ROS within mitochondria and seems to
be also required for cytochrome c release and opening of the
permeability transition pore, which is crucial for apoptosis
[40]. It remains to be clariﬁed, what exact role p66shc plays
in the aging process and how it is connected to other aging-
relevant pathways.
In conclusion, the exact relationship between mitochon-
dria, oxidative stress, and aging has not yet been settled. An
import aspect to consider is that oxidativedamage is the sum
ofactualROSproduction,capacityofthecellularantioxidant
defense and last the clearance of damaged molecules by
repair or protein degradation. Any of these factors might
contribute to increased oxidative damage, so that, for exam-
ple, under normal ROS production, defective clearance of
damaged molecules results in increased oxidative damage.
Hence oxidative damage has to be carefully assessed in
the context of ROS production, antioxidant response and
damage control.Journal of Aging Research 3
3.The PeroxisomeProliferator-Activated
Receptor (PPAR) γ Coactivatorα(PGC-1α)
and Mitochondrial Biogenesis
Mitochondria derive from dual genetic origin, the nuclear
and mtDNA, so that biosynthesis from both genomes has
to be coordinated. Mammalian mitochondria have been esti-
mated to have up to ∼1500 proteins. The vast majority of
these proteins including structural genes and assembly
factorsformitochondrial proteinsare encodedin thenuclear
DNA,aresynthesized inthecytoplasmandare importedinto
mitochondria. mtDNA encodes only for 13 subunits of the
OXPHOS enzymes CI, III, IV, and V as well as 2 rRNAs and
22tRNAs.Expression of mtDNA-encodedproteins and RNA
species is governed by the mitochondrial transcription and
translation machinery, whose protein factors are encoded in
the nuclear DNA [41].
It is now apparent that a relatively small number of
nuclear factors serve to coordinate the transcriptional exp-
ression of nuclear and mitochondrial respiratory proteins.
Among these are the nuclear respiratory factors NRF-1 and
NRF-2(GA bindingprotein, GABP),which are implicated in
theexpression ofmitochondrial genes(Figure1).Inaddition
to the NRFs, stimulatory protein 1 (Sp1), estrogen related
receptor α (ERRα), and yin yang 1 transcription factor
(YY1) have also been linked to many genes required for
respiratory chain expression and function. These factors are
controlled by a common key component, namely, perox-
isome proliferator-activated receptor (PPAR) γ coactivator
α (PGC-1α)[ 42]. PGC-1α is a transcriptional coactivator
andinteractswithnuclearreceptorsandtranscriptionfactors
to activate transcription of their target genes [43]. PGC-
1α activity is responsive to multiple stimuli including but
not limited to nutrient availability, calcium, ROS, insulin,
thyroid and estrogen hormone, hypoxia, ATP demand, and
cytokines [43].
Besides PGC-1α, other members of the PGC-1 family of
coactivators, namely PGC-1β and PGC-related coactivator
(PRC), are also implicated in modulating mitochondrial
function, but their exact role is not understood [42]. Also,
it is likely that other, yet unidentiﬁed factors, are involved in
orchestrating mitochondrial biogenesis.
PGC-1α is the ﬁrst responder to stimuli and interacts
with transcription factors such as NRF1, which is an inter-
mediate transcription factor which stimulates the synthesis
of TFAM (Figure 1). TFAM is crucial for mtDNA transcrip-
tion and in addition plays an important role in mtDNA
maintenance and mtDNA nucleoid formation [44].
PGC-1α activity is regulated on both the expression and
posttranslational level (Figure 1): expression is mainly reg-
ulated by the peroxisome proliferator-activated receptors
(PPAR) and other tissue-speciﬁc factors such as cAMP res-
ponsive element (CREB) in skeletal muscle. PPARs respond
to external stimuli and metabolic demands and by activating
PGC-1α, they link this changes to mitochondrial biogenesis
[41]. Activation of PPARs by pharmacological agonists used
in treatment for metabolic syndrome successfully induced
mitochondrial biogenesis [45–47]. Recently, it has been
found that PGC-1α expression is decreased by methylation
of the promoter by DNA methyltransferase 3b (DNMT3B)
[48]. This kind of regulation leads to long-lasting changes
in PGC-1α transcription and might be potentially relevant
in several pathophysiologies. PGC-1α regulates its own tran-
scription via YY1. YY1 is a common target of mammalian
target of rapamycin (mTOR) and PGC-1α.m T O Rd i r e c t l y
modulates the physical interaction of PGC-1α with YY1
and thereby modulates mitochondrial activity. Decrease in
mTOR activity likely inhibits YY1-PGC-1α function result-
ing in decreased expression of mitochondrial genes [42, 43].
Very littleis known about negative regulators of PGC-1α.
So far, only RIP140 and 160MYP have been identiﬁed. Both
molecules suppress mitochondrial biogenesis [49, 50].
PGC-1α activity can also be modulated by posttrans-
lational modiﬁcations. AMPK, Akt and p38 MAPK target
PGC-1α phosphorylation sites. Important key players in this
respect aretheAMP-activatedkinase(AMPK)andthesirtuin
Sirt1 [51]. AMPK is involved in the adaptive response to
energy deﬁcit. Direct phosphorylation by AMPK not only
activates PGC-1α, but also promotes PGC-1α-dependent
induction at the PGC-1α promoter [51]. Activity of PGC-
1α is also regulated through inhibitory acetylation by GCN5
and stimulatory deacetylation through Sirt1 [51]. Sirt1 is
a member of the Sirtuin family that has been implicated
in longevity in yeast, worms and ﬂies [4]. Activation of
Sirt1 through caloric restriction induces PGC-1α activity
and enhances mitochondrial function [52, 53]. While it is
observed that resveratrol indirectly activates PGC-1α and
induces mitochondrial biogenesis [52, 53] it is under dispute
whether this indirect mechanism involves Sirt1 or might
function indirectly through AMPK [54, 55].
Since AMPK senses AMP/ATP ratios and Sirt1 is NAD+
dependent, both AMPK and Sirt1 modulate PGC-1α activity
in response to cellular energy supply. Insulin reduces PGC-
1α expression, but also induces phosphorylation of PGC-1α
through Akt and thereby inhibits its activity [56, 57]. The
p38 mitogen-activated protein kinase (p38 MAPK) phos-
phorylates and activates PGC-1α [58]. This phosphorylation
enhances PGC-1α half-life, disrupts interaction with the
corepressor p160MBP in myoblasts and thereby enhances
PGC-1α cotranscriptional activity [49]. PGC-1α is also
phosphorylated byglycogensynthase kinase 3β (GSK3β)and
thereby inhibited under oxidative stress [59]. However, Sirt1
is activated under the same conditions and activates PGC-1α
by deacetylation. It is so far unclear how Sirt1 and GSK3bact
in concert to modulate PGC-1α activity.
Recentworkalso identiﬁesSUMOylation,ubiquitination
as well as O-linked β-N-acetylglucosamination and methy-
lation suggesting that PGC-1α activity can be ﬁne-tuned
depending on cellular needs by various ways [60, 61].
4.Mitochondrial Functionand PGC-1αin
Age-RelatedPathologiesofMuscle,Heart,
Liver,and Brain
Aging is most likely a multifactorial process. Recent ﬁndings
suggest a causal role of mitochondrial dysfunction in the4 Journal of Aging Research
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Figure 1: Modulation of PGC-1α and its targets. Regulation of PGC-1α activity on transcriptional and posttranscriptional levels as well as
by interaction with inhibitory factors is summarized. The diagram shows the PGC-1α targets that are involved in metabolic regulation of
mitochondria. The details are discussed in the text.
agingprocessandacentralroleformitochondrial adaptation
in the mechanism of aging retardation by caloric restriction
and exercise. Mitochondrial disorders often present as neu-
rological disorders, but can manifest as myopathy, diabetes,
multipleendocrinopathy,or a variety ofothersystemic man-
ifestations [62]. During aging, the decline of mitochondrial
function often correlated with the onset and progression of
similar pathologies [63, 64].
Many other factors have been discussed to play major
rolesintheagingprocessincludingmTOR,Sirt1andinsulin/
IGF signaling as well as stem cell aging [65]. Sirt1 is clearly
connected to PGC-1α function. Also, mTOR and PGC-1α
pathwaysarelinkedthroughYY1(seeabove).Thisregulation
would allow the cell to connect nutrient pathways to
activatemitochondrialfunctionandensureenergysupplyfor
cellular activities. Very recently, also a connection between
telomeredysfunction, an additionalplayerin causingcellular
senescenceandage-relatedpathology,andthePGC-family of
coactivators was established [66].
Mitochondria are the most damaged organelle during
aging. Hence removal and synthesis are necessary for proper
energy homeostasis. An increase in mitochondrial turnover
might be beneﬁcial for cells resulting in better maintenance
of the organelle. PGC-1α, poised centrally in multiple
pathways aﬀecting mitochondrial dysfunction and cellular
function should play a key role in this prevention. Age-
associated reductions in PGC-1α itself as well as in modu-
lating proteins such as AMPK activity may be an important
contributing factor in the reduced mitochondrial function
associated with aging [67, 68].
The role of mitochondrial and PGC-1α likely aﬀects
diﬀerent tissue. The following paragraph focuses on the
eﬀect in skeletal muscle, heart, liver, and brain, since those
are the tissue, where PGC-1α function is best understood
(Figure 2).
4.1. Skeletal Muscle and Sarcopenia. PGC-1α seems to be
mediator of many known beneﬁcial eﬀects of exercise on
muscle physiology. In skeletal muscle, PGC-1α expression is
linked to muscle contraction [69]. A major mediator is the
activation of Ca2+/calmodulin-dependent protein kinase IV
(CamKIV) and calcineurin A, which are activated through
the changes in calcium within the muscle in response to
exercise. The heightened calcium signaling activates several
important transcription factors such as CREB, which is a
target of CamKIV, and myocyte enhancer factors 2 (MEF)
[70] .A n o t h e rf a c t o rt h a tr e g u l a t e sP G C - 1 α expression upon
exercise involves p38 MAPK, which activates MEF2 and
transcription factor 2 (ATF2). p38 MAPK in conjunction
with ATF2 results in increased expression of PGC-1α [71].
p38 MAPK also stimulates PGC-1α by phosphorylation in
response to cytokinestimulation in musclecells [72]. Finally,
also AMPK as an ATP gauge is activated by exercise and
enhancing PGC-1a transcription as well as activity (see
above). The changed transcription program upon exercise
induces changes in muscle plasticity such as a ﬁber-type
switching towards more oxidative ﬁbers and induces the
mitochondrial antioxidant program [70, 73, 74].
PGC-1α is also involved in regulation of muscle function
and integrity: PGC-1α regulates the neuromuscular junction
program by being recruited to GABP-complex to stimulate
a broad neuromuscular junction gene program [75]. In
addition, PGC-1αinhibitsFoxO3activity ontranscription of
atrophy-speciﬁc genes and thereby decreases muscle atrophy
[76]. Transgenic PGC-1α mice show smaller decrease in
muscle ﬁber diameter and smaller induction of atrogenes in
denervation-induced muscle atrophy and aging muscle by
suppressing FoxO3 action [68, 76].
Additionally, increased muscular PGC-1α seems to be
involved in the regulation of apoptosis and protein degrada-
tion during aging [68]. Loss of function studies in PGC-1α
knockoutanimals additionalsuggestthatPGC-1αmodulates
local or systemic inﬂammation and might regulate the exp-
ression of inﬂammatory cytokines and inﬂammatory mark-
e r ss u c ha sT N F α and IL6 [77, 78], but the exact mechanism
that links PGC-1α and the inﬂammatory response is not
known.PGC-1αadditionallycontrolsangiogenesisinmuscle
by controlling VEGF expression and thus improves delivery
of oxygen and substrates to muscle tissue [79].
Intheagingmuscle,zonesofmetabolicallyinactivetissue
have been observed due to expansion of mitochondria that
become damaged during aging [80]. This mitochondrialJournal of Aging Research 5
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Figure2:Tissue-speciﬁcfunctionofPGC-1αrelevanttoage-related pathologies.Diﬀerent functionsofPGC-1αinheart,liver,brain,skeletal
muscle and heart are depicted. These functions might be beneﬁcial in age-associated pathologies as described in detail in the text.
dysfunction has been implicated in the development of
sarcopenia, the age-related muscle loss [81].
Several studies have shown that elevated PGC-1α levels
and maintenance of mitochondrial function in muscle pre-
vent muscle wasting in muscular disorder such as mitochon-
drial myopathy [46], denervation-induced muscle atrophy
[76] and Duchenne muscular dystrophy [75]. Elevated PGC-
1α levels also have a therapeutic eﬀect on the onset and
progression of age-related loss of muscle mass (sarcopenia)
[68]: here, transgenic muscle-speciﬁc expression of PGC-1α
signiﬁcantly reducedthe loss of musclemass and maintained
exercise capacity during the aging process. The elevated
PGC-1α levels in the aging muscle increased mitochondrial
content and thereby maintained ATP supply. Additionally,
transgenic PGC-1α mice showed decreased markers for
apoptosis and proteolysis as well as a balanced autophagy,
which most likely resulted in the decreased muscle atrophy.
Thismaintenance ofmusclemass intransgenic PGC-1αmice
was associated with a “younger” neuromuscular junction
phenotype and decreased ﬁbrosis, which most likely also
contributedtoan improvedmusclefunction. Theprevention
of sarcopenia in mice with elevated PGC-1α and mainte-
nance of muscle as a metabolic tissue resulted in improved
insulinsensitivity and preventedhypoglycemia duringaging.
Additionally, muscle-speciﬁc PGC-1α expression also ame-
liorated other pathological factors observed during aging on
a systemic level: elevated muscle PGC-1α levels decreased
gain of fat mass and osteoporosis in mice. Additionally, the
level of circulating inﬂammatory markers usually observed
during aging and in part be caused by the muscle atrophy
were markedly reduced in transgenic PGC-1α animals [68].
While the precise mechanism of the observed protective
eﬀects is not entirely clear, the following possibilities could
explaintheeﬀectofPGC-1α:theregulationofmitochondrial
mass might help to prevent the energy crisis associated with
many muscular diseases [46, 68]. PGC-1α also reduces the
transcription of atrophy-speciﬁc genes by inhibiting FoxO3
[76]. Additionally, de novo protein synthesis is activated and
the neuromuscular junction is stabilized [75]. Apoptosis
and protein degradation, which are hallmarks of muscle
wasting, are reduced [68]. These eﬀects likely contribute to
the antimuscle wasting properties of PGC-1α. Maintenance
of the metabolic properties of the muscle tissue as well as
prevention of the muscle atrophy most likely resulted in
the observed systemic eﬀects underlining the importance of
muscle function and integrity for whole-body function.
4.2. Heart and Age-Related Cardiovascular Disorders. In the
heart, PGC-1α strongly induces mitochondrial function and
fatty acid oxidation [82]. Normal growth and response to
exercise are controlled by PGC-1α similar to skeletal muscle
[83, 84]. Absence of PGC-1α in the heart reduces the cardiac
reserve under stress conditions and diminished the cardiac
capacity under exercise conditions [85, 86]. In the failing
heart, as what occurs in heart diseases and during aging,
metabolism is switched from fatty acid to glucose utilization
and expression of PGC-1α is reduced [87]. In contrast to
skeletal muscle, muscle elevated PGC-1α seems to have an
adverse eﬀectinheart: elevatedincreased expression ofPGC-
1α in the heart causes cardiomyopathy and heart failure
in mice [88]. Also, transient activation of PGC-1α dimin-
ishes cardiac contractile recovery after ischemia-reperfusion
injury [89]. These ﬁndings suggest that PGC-1α levels in
heart need to be tightly regulated to prevent pathology.
The adverse eﬀect of PGC-1α might be attributed to tissue-
speciﬁc diﬀerences in the availability of transcription factor
partners for PGC-1α,d i ﬀerences in cell signaling or other
heart-speciﬁc metabolic requirements.
Despite these eﬀects of elevated PGC-1α in the heart,
PGC-1α may nevertheless aﬀect cardiac function. Sirt1 and
PPARα, two proteins that regulate PGC-1α expression and
activity,aremajorplayersinprotectingtheheartfromtypical
age-related pathologies such as hypertrophy, metabolic dys-
regulationandinﬂammation [53].Theseeﬀectscouldbealso6 Journal of Aging Research
observed by administration of resveratrol, which is also an
indirect activator of PGC-1α implying that a PGC-1α might
be involved in the cardioprotective eﬀect.
A major factor contributing to the development of heart
disorders during aging is the failing vasculature. PGC-1α
seems to have an important role in the vasculature wall itself
[90].Endothelialdysfunction isanearly feature ofcardiovas-
cular disease and is associated with increased levels of ROS.
The antioxidant property of PGC-1α might hence be beneﬁ-
cial to maintain vasculature function and thus contribute to
the prevention of cardiovascular diseases. Indeed, activation
of PGC-1α in endothelial cells prevents oxidative damage
and cellular apoptosis and prevents endothelial dysfunction
in vivo [90]. It remains to be seen what eﬀect endothelial
PGC-1α has on angiogenesis and atherosclerosis, two major
contributing factors of cardiovascular disease.
4.3.Brain andAge-RelatedNeurodegenerativeDiseases. PGC-
1αisexpressedinallbraintissuesandplaysanimportantrole
in normal brain function and a major role in the oxidative
stress response [91]. In mice, PGC-1α deﬁciency causes
behavioral changes including anxiety and hyperactivity as
well as hind limb clasping. These behavioral changes are
associated with spongiform-like vacuolization primarily in
the striatum associated with gliosis and leads to reduced
expression of several brain-speciﬁc genes that are all asso-
ciated with normal brain function. Substantia nigra and
CA1 neurons are more susceptible to neurodegeneration in
response to neurotoxins suggesting an important role of
PGC-1α in neuronal maintenance [92]. PGC-1α also seems
to be involved in the control of neurite growth and neuronal
synaptic function [93].
While mitochondrial dysfunction aﬀects the whole orga-
nisms during aging its eﬀects might be especially deleterious
at the level of the CNS [94]. PGC-1α might potentially
relieve this defect and together with the above described
brain-speciﬁc functioninﬂuenceage-associatedneurodegen-
eration. In fact, PGC-1α has been implicated in the onset
and progression of neurodegenerative diseases. Postmortem
brain samples of patients with Huntington’s disease (HD)
h a dad e c r e a s e dl e v e lo fP G C - 1 α mRNA [95, 96]. Polymor-
phismisalso associated withtheonsetofAD[97].PGC-1αis
repressed by amutant formofthe Huntingtonproteinwhich
leads to mitochondrial dysfunction and neurodegeneration.
Over-expressionofPGC-1αrescuescellsfromthedeleterious
eﬀect of Huntington’s, whereas loss of PGC-1α in HD mice
aggravated neurodegeneration [95]. Moreover, PGC-1α KO
miceshow Huntington’slikephenotypeandneuronal lesions
suggesting that PGC-1α is crucial for maintenance of striatal
function. Additionally, PGC-1α SNPs are associated with the
ageofonsetofHD.InaPDmousemodel,PGC-1αdeﬁciency
caused an increased degeneration of dopaminergic neurons
in the substantia nigra associated with oxidative damage
[91].
Interestingly, activators of PGC-1α such as resveratrol
have a neuroprotective eﬀect in acute and chronic brain
injury as well as in neurodegenerative diseases suggesting a
role for PGC1-α in modulating the outcome of the disease
[98].
4.4. Liver and Metabolic Disorders. In liver, PGC-1α is in-
duced by fasting in response to glucagon and regulates most
of the metabolic changes that occur during the transition
from fed to fasted state [99]. The most relevant metabolic
pathways in this regard are gluconeogenesis, fatty-acid-beta
oxidation, ketogenesis, and heme biosynthesis [5]. Absence
of PGC-1α results in a blunted hepatic fasting response as
well asfasting hypoglycemia andhepaticsteatosis [86].PGC-
1α associates in liver with several transcription factors such
as HNF4-αand FoxO1and thereby inducesthe expression of
severalgluconeogenicenzymes [100, 101].Glucagoninduces
cAMP and CREB as well as p38 MAPK over cAMP and
PKA [102]. p38 MAPK increases PGC-1α transcription as in
muscle and seems to be also necessary for the expression of
PGC-1α in response to free fatty acids to stimulate gluco-
neogenesis [103].
There has also been considerable interest in mitochon-
drial dysfunction asa contributingfactor in thedevelopment
of metabolic disorders. Although the involvement of mito-
chondrial dysfunction in insulin resistance is under dispute
[104–106], several lines of evidence suggest that decreased
mitochondrial function may be the underlying defect that
causes insulin resistance during aging: the age-associated
decline in mitochondrial function in elderly might con-
tribute to the age-related insulin resistance [68, 107]. In-
crease in mitochondrial function during aging increases fuel
handling, fatty acid oxidation and protects from insulin
resistance [52, 68, 108, 109].Interestingly, PGC-1α promoter
methylation and hence decreased PGC-1α expression in
skeletal muscle was found to be more prevalent in patients
with diabetes compared to healthy subjects [48]. In addition,
mitochondrial functional insuﬃciency and decreased PGC-
1α levels have been found in the insulin-resistant oﬀspring
of patients with T2D. The fact that this occurs in healthy
individuals that are not diabetic suggests that an inherent
defect in oxidative phosphorylation may be a contributing
factor [110]. Severeness of steatosis is associated with
impaired PGC-1α expression and reduced mitochondrial
gene expression [111]. Interestingly, rosiglitazone attenuates
age-associatedliverpathologyinnonalcoholicsteatohepatitis
[112]. Rosiglitazone is indirectly activating PGC-1α via
PPAR, implying that PGC-1α activating is beneﬁcial in liver
pathologies.
4.5. Role of PGC-1α Responsive Proteins in Age-Related Patho-
logies. Also downstream targets of PGC-1α may play a role
in lifespan regulation and maintenance of tissue func-
tion. Over-expression of TFAM, for example, can reverse
age-dependent memory impairment in mice, presumably
through the prevention of mitochondrial dysfunction in
microglia [113]. Over-expression of TFAM also protects
against beta-amyloid-induced oxidativedamage[114]an din
additionseems to be also a target for therapeuticstrategies in
cardiac failure [115].
Both NRF1 and NRF2 have a broad spectrum of target
genes besides mitochondrial genes. A screen for NRF1 bind-
ing sites revealed signiﬁcant overlap to E2F, a transcription
factor family which is involved in the regulation of cell
growth. NRF1 is also involved in the regulation of theJournal of Aging Research 7
expression fragile X mental retardation-1 gene and NRF1
promoter binding is increased in the mouse brain during
aging which might be linked to the age-related deﬁciency in
learning, memory, and cognition [116]. NRF2 is implicated
intheregulationofthe cellcycle,myeloid genes, T-cell devel-
opment and other target genes [117, 118]. In muscle, NRF2
regulates the transcription of the nicotinic acetylcholine
receptor and utrophin genes and plays a crucial role in
formation and maintenance of the neuromuscular junction
[119]. In conjunction with PGC-1α, NRF2 (GABP) regulates
the NMJ program [75]( s e ea b o v e ) .
AnovelidentiﬁedtargetofPGC-1αisthemitochondrial-
localized Sirtuin 3 (Sirt3) [120]. Sirt3 is a major player in
mitochondrial biogenesis, regulation of metabolic enzymes
and ROS suppression [121]. Recent ﬁndings show that
Sirt3 also targets the mitochondrial permeability transition
pore (mPTP) and prevents mPTP opening by modulating
cyclophilinD[122].mPTP opening playsa fundamental role
inmyocardial celldeathandthedevelopmentofheartdisease
[123].
5.Mitochondria and PGC-1αin
AntiagingStrategies
There is an abundance of studies that provide indirect and
direct evidence in support of a role for PGC-1α and regu-
lation of mitochondrial function in antiaging strategies. As
outline above, therapeutic modulation of PGC-1α has huge
potential for treatment of patients with various mitochon-
drial dysfunction associated with disease and age-related
disorders. In the following, antiaging strategies targeting
mitochondria and PGC-1α in controlling age-related pathol-
ogy are discussed.
5.1. Caloric Restriction. CR has been shown to induce long-
evity in many diﬀerent organisms and is a common treat-
ment for sarcopenia andinsulin resistance [124–128].Recent
ﬁndings suggest a central role for mitochondrial adaptation
in the mechanism of aging retardation by CR [4]. The
decline in oxidative capacity in skeletal muscle during aging
is prevented in CR animals [63, 129]. The slower decline of
PGC-1αgeneexpressionduringaginginCRanimalssuggests
a better maintenance of mitochondrial biogenesis during
aging [63].
CR has been shown to exert a positive eﬀect on mito-
chondria, boosting mitochondrial activity and hence pro-
viding some of the salutary eﬀects of CR [3, 4]. The
eﬀects of CR are thought to be mediated by the regulatory
family of sirtuins, mainly SIRT1,an NAD-dependentprotein
deacetylase [4]. Sirt1 has many proven targets involved in
protein homeostasis and metabolisms [130]. Among them is
PGC-1α [131]. Additionally, Sirt1 activates the endothelial
nitric oxide synthase eNOS, which stimulates mitochondrial
activity [132]. The resulting increase in mitochondrial
activity is thought to be related to longevity eﬀect of CR and
Sirt1 upregulation. In caloric-restricted mice, Sirt1 activity
is increased and protects form cancer, neurodegeneration,
inﬂammatory disorders, metabolic, and cardiovascular dis-
ease [133]. Intriguingly, enforced Sirt1 activity seems to
result in a CR-like physiology and protection from degenera-
tive diseases [133, 134]. Recent evidencesuggests that Sirt1 is
also involved in mediating the response to dietary restriction
and increasing health span in humans [64].
5.2.Exercise. Exerciseisanexcellenttherapeuticintervention
for conditions such as obesity, T2D, neurodegeneration,
osteoporosis and sarcopenia [135, 136]. PGC-1α activation
seems to be the mechanism that mediates those beneﬁcial
eﬀects and increased PGC-1α levels promote an exercised
phenotype [74, 137, 138]. Exercise also causes a reduction
in the levels of systemic inﬂammation after exercise, pre-
sumably through the same mechanisms [139]. Exercise also
activates the AMP-activated kinase (AMPK) [140]. AMPK
is considered to be a key metabolic sensor that increases
translocation of Glut4 to the plasma membrane [141].
AMPK also activates PGC-1α and thereby mitochondrial
biogenesisinanattempttocompensatefortheATPdepletion
[137, 142]. This mechanism is thought to be the molecular
basis for the therapeutic eﬀect of exercise, which stimulates
AMPK. Activation of PGC-1α in skeletal muscle has thereby
the potential to compensate for mitochondrial dysfunction
and aﬀect other pathways and thusprevent insulin resistance
a ss h o w ni na na n i m a lm o d e l[ 68, 74, 143].
5.3. Pharmacological Approaches. In addition to exercise,
PGC-1α and hence mitochondrial biogenesis can be acti-
vated by a wide array of pharmacological substances. PGC-
1α activity is controlled by the PPARs, AMPK and Sirt1
(Figure 2). Thus, drugs that activate PPARs, AMPK and
Sirt1 could potentially result in PGC-1α activation. Such
pharmaceutical activators include ﬁbrates and rosiglitazone
(PPAR), metformin and AICAR (AMPK) as well as resver-
atrol (Sirt1). Induction of mitochondrial biogenesis and/or
PGC-1α activation has been demonstrated for most of these
substances both in vitro and in vivo [45–47, 52, 141, 144].
Interestingly,bezaﬁbrate administration toamouse modelof
mitochondrial myopathy mimicked the eﬀects of transgenic
PGC-1α expression [46]. In mice, resveratrol prevents the
decreased lifespan associated with obesity [52]. It remains
to be seen what how pharmaceutical stimulated PGC-1α
activation aﬀects aging and lifespan.
6.Conclusion
Mitochondria have been implicated in the aging process and
the onset and progression of age-associated diseases since
decades. While the impact of mitochondrial ROS is in
question,failing ATPsupplydueto increasing mitochondrial
dysfunction seems to be a major contributing factor to
the aging process. Modulating mitochondrial function and
aﬀecting several tissue-speciﬁc pathways by PGC-1α have
been shown to have a beneﬁcial eﬀect. Notably,existing anti-
aging strategies as well as studies in mice suggest an impor-
tant role of mitochondrial function and the PGC-1α cascade
in the preventing of age-associated diseases. In the same8 Journal of Aging Research
line, control and maintenance of mitochondrial function
by PGC-1α activation have a huge therapeutic potential for
age-related pathologies such as insulin resistance, sarcopenia
and neurodegeneration. Findings on elevated PGC-1α levels
in the heart caution against the systemic eﬀects of elevated
PGC-1α levels. Beneﬁcial eﬀects seem to be tissue speciﬁc,
and remaining within a therapeutic window will be impor-
tant.
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